American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 1(66), 2022
DOI: 10.1128/aac.01584-21
Full text: Download
Despite repeated malaria infection, individuals living in areas where malaria is endemic remain vulnerable to reinfection. The Janus kinase (JAK1/2) inhibitor ruxolitinib could potentially disrupt the parasite-induced dysfunctional immune response when administered with antimalarial therapy.